Skip to main content
Year archive

Grand Pharmaceutical Group Limited — 2021 filings

All 72 regulatory filings released by Grand Pharmaceutical Group Limited (512) in 2021, sourced directly from the official regulator.

72 Filings
2021 Period
2021 filings (72)
Filing Released Lang
VOLUNTARY ANNOUNCEMENT: HE GROUP AND THE GERMAN ITM COMPANY ENTERED INTO AN EXCLUSIVE LICENSING AGREEMENT FOR GLOBAL INNOVATIVE RADIONUCLIDE-DRUG CONJUGATES
Regulatory Filings
2021-12-27 English
VOLUNTARY ANNOUNCEMENT: THE GLOBAL INNOVATIVE RADIONUCLIDE-DRUG CONJUGATES PRODUCT TLX591-CDx WAS APPROVED FOR COMMERCIALIZATION IN THE UNITED STATES
Regulatory Filings
2021-12-21 English
CONNECTED TRANSACTIONS: 1) PRODUCT REGISTRATION CONSULTANCY AGREEMENT&#x3b; 2) TECHNOLOGY INTRODUCTION CONSULTANCY COOPERATION AGREEMENT&#x3b; AND 3) TECHNOLOGY CONSULTANCY SERVICES AGREEMENT
Regulatory Filings
2021-12-20 English
VOLUNTARY ANNOUNCEMENT: THE GLOBAL INNOVATIVE PRODUCT STC3141 OF THE GROUP HAS COMPLETED THE ENROLLMENT AND DOSING OF ALL PATIENTS IN THE PHASE IIa CLINICAL TRIAL FOR THE TREATMENT OF COVID-19 IN EURO
Regulatory Filings
2021-12-14 English
CONTINUING CONNECTED TRANSACTIONS
Regulatory Filings
2021-12-09 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 NOVEMBER 2021
Regulatory Filings
2021-12-03 English
VOLUNTARY ANNOUNCEMENT: THE GROUP INTRODUCED GLOBAL INNOVATIVE MITRAL VALVE REPLACEMENT MEDICAL DEVICE
Capital/Financing Update
2021-11-28 English
(1) CHANGE OF COMPANY NAME AND COMPANY LOGO&#x3b; (2) CHANGE OF ENGLISH STOCK SHORT NAME
Regulatory Filings
2021-11-12 English
VOLUNTARY ANNOUNCEMENT: THE GLOBAL INNOVATIVE DRUG OF THE GROUP STC3141 SUCCESSFULLY DOSED THE FIRST PATIENT OF ITS PHASE Ib CLINICAL TRIAL FOR ARDS IN CHINA
Regulatory Filings
2021-11-09 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 OCTOBER 2021
Regulatory Filings
2021-11-02 English
VOLUNTARY ANNOUNCEMENT: THE GLOBAL INNOVATIVE DRUG RYALTRIS COMPOUND NASAL SPRAY HAS BEEN GRANTED PHASE THREE CLINICAL TRIAL APPROVAL
Regulatory Filings
2021-10-20 English
VOLUNTARY ANNOUNCEMENT: THE GROUP PROPOSED TO ACQUIRE 80% EQUITY OF AN AMINO ACID MANUFACTURING COMPANY
Capital/Financing Update
2021-10-18 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 SEPTEMBER 2021
Regulatory Filings
2021-10-07 English
POLL RESULTS OF THE SPECIAL GENERAL MEETING HELD ON 30 SEPTEMBER 2021 AT 11:15 A.M.
Declaration of Voting Results & Voting Rights Announcements
2021-09-30 English
POLL RESULTS OF THE SPECIAL GENERAL MEETING HELD ON 30 SEPTEMBER 2021 AT 11:00 A.M.
Declaration of Voting Results & Voting Rights Announcements
2021-09-30 English
INTERIM REPORT 2021
Interim / Quarterly Report
2021-09-23 English
CHANGE OF BOOK CLOSURE PERIOD IN RELATION TO SPECIAL GENERAL MEETINGS
Regulatory Filings
2021-09-14 English
Proxy Form: For the special general meeting to be held on 30 September 2021 or any adjournment thereof
Proxy Solicitation & Information Statement
2021-09-13 English
Notice of Special General Meeting
AGM Information
2021-09-13 English
Connected Transaction: Amended Total Return Swap Transaction with Natixis
Proxy Solicitation & Information Statement
2021-09-13 English
Proxy Form: For the special general meeting to be held on 30 September 2021 or any adjournment thereof
Proxy Solicitation & Information Statement
2021-09-13 English
Notice of Special General Meeting
Proxy Solicitation & Information Statement
2021-09-13 English
(1) Revision of the Existing Annual Caps Regarding the Continuing Connected Transactions&#x3b; (2) Proposed Change of Company Name&#x3b; and (3) Notice of the SGM
Proxy Solicitation & Information Statement
2021-09-13 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 AUGUST 2021
Regulatory Filings
2021-09-02 English
FURTHER DELAY IN DESPATCH OF CIRCULAR IN RELATION TO THE (1) REVISION OF THE EXISTING ANNUAL CAPS REGARDING THE CONTINUING CONNECTED TRANSACTIONS AND (2) PROPOSED CHANGE OF COMPANY NAME
Report Publication Announcement
2021-09-01 English
DELAY IN DESPATCH OF CIRCULAR: IN RELATION TO THE AMENDED TOTAL RETURN SWAP TRANSACTION WITH NATIXIS
Report Publication Announcement
2021-09-01 English
ADOPTION OF SHARE AWARD SCHEME
Share Issue/Capital Change
2021-09-01 English
(1) REVISION OF THE EXISTING ANNUAL CAPS REGARDING THE CONTINUING CONNECTED TRANSACTIONS AND (2) PROPOSED CHANGE OF COMPANY NAME: DELAY IN DESPATCH OF CIRCULAR
Report Publication Announcement
2021-08-17 English
CONNECTED TRANSACTION: AMENDED TOTAL RETURN SWAP TRANSACTION WITH NATIXIS
Capital/Financing Update
2021-08-11 English
VOLUNTARY ANNOUNCEMENT: PROPOSED ADOPTION OF A SHARE AWARD SCHEME
Capital/Financing Update
2021-08-10 English
2021 INTERIM RESULTS ANNOUNCEMENT
Interim / Quarterly Report
2021-08-10 English
VOLUNTARY ANNOUNCEMENT: THE GROUP INTRODUCED A GLOBAL INNOVATIVE ADVANCED HEART FAILURE THERAPEUTIC SYSTEM
Regulatory Filings
2021-08-05 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JULY 2021
Regulatory Filings
2021-08-03 English
VOLUNTARY ANNOUNCEMENT: THE GROUP OBTAINED THE COMMERCIALIZATION RIGHTS OF AN EPINEPHRINE AUTO-INJECTOR FOR THE TREATMENT OF ANAPHYLAXIS IN MAINLAND CHINA, MACAU AND TAIWAN
Capital/Financing Update
2021-08-02 English
VOLUNTARY ANNOUNCEMENT: THE GROUP ESTABLISHED OVERSEAS R&D PLATFORM IN THE FIELD OF CEREBRO-CARDIOVASCULAR PRECISION INTERVENTIONAL DEVICES AND JOINTLY DEVELOPING A GLOBAL INNOVATIVE INTRAVASCULAR
Capital/Financing Update
2021-08-02 English
DATE OF BOARD MEETING
Regulatory Filings
2021-07-29 English
POSITIVE PROFIT ALERT
Regulatory Filings
2021-07-27 English
(1) REVISION OF THE EXISTING ANNUAL CAPS REGARDING THE CONTINUING CONNECTED TRANSACTIONS&#x3b; AND (2) PROPOSED CHANGE OF COMPANY NAME
Regulatory Filings
2021-07-16 English
CONNECTED TRANSACTION: ACQUISITION OF MINORITY INTEREST IN A NON-WHOLLY OWNED SUBSIDIARY
Capital/Financing Update
2021-07-13 English
VOLUNTARY ANNOUNCEMENT: ONCOSEC ENTERS INTO A COLLABORATION AGREEMENT WITH MERCK FOR A PIVOTAL GLOBAL PHASE III STUDY OF TAVO COMBINED WITH KEYTRUDA FOR LATE- STAGE METASTATIC MELANOMA
Regulatory Filings
2021-07-08 English
VOLUNTARY ANNOUNCEMENT: TADALAFIL TABLETS WAS GRANTED A DRUG REGISTRATION CERTIFICATE
Regulatory Filings
2021-07-07 English
VOLUNTARY ANNOUNCEMENT: TLX250-CDX DOSED THE FIRST PATIENT WITH THE EXPANDING INDICATION BLADDER CANCER IN AUSTRALIA
Regulatory Filings
2021-07-07 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 JUNE 2021
Share Issue/Capital Change
2021-07-02 English
CONNECTED TRANSACTIONS: (1) SUBSCRIPTION FOR NEW SHARES IN GRAND PHARMA SPHERE PTE LTD. AND (2) TOTAL RETURN SWAP TRANSACTION WITH NATIXIS
Capital/Financing Update
2021-07-02 English
VOLUNTARY ANNOUNCEMENT: THE GROUP OBTAINED THE DEVELOPMENT AND COMMERCIALIZATION RIGHTS OF AN IMPROVED NEW DRUG FOR ANTI-INFLAMMATORY AND PAIN RELIEF AFTER OPHTHALMOLOGY SURGERY IN MAINLAND CHINA, HON
Capital/Financing Update
2021-06-03 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MAY 2021
Share Issue/Capital Change
2021-06-02 English
VOLUNTARY ANNOUNCEMENT: TLX591-CDx DOSED THE FIRST PATIENT IN JAPAN&#x3b; AND TLX591 WAS APPROVED FOR PHASE III CLINICAL TRIALS IN AUSTRALIA
Regulatory Filings
2021-06-02 English
List of Directors and their Role and Function
Board/Management Information
2021-06-01 English
(1) POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 1 JUNE 2021&#x3b; (2) RETIREMENT AND APPOINTMENT OF EXECUTIVE DIRECTORS&#x3b; (3) CHANGE OF CHIEF EXECUTIVE OFFICER OF THE COMPANY&#x3b; AND (4)
Declaration of Voting Results & Voting Rights Announcements
2021-06-01 English
VOLUNTARY ANNOUNCEMENT: THE GROUP EXCLUSIVELY INTRODUCED THE NEW GENERATION HEARTLIGHT X3 LASER ABLATION PLATFORM OF THE GLOBAL INNOVATIVE BREAKTHROUGH MEDICAL DEVICE HEARTLIGHT ENDOSCOPIC ABLATION SY
Capital/Financing Update
2021-05-30 English
VOLUNTARY ANNOUNCEMENT: THE GROUP OBTAINED ALL DEVELOPMENT AND COMMERCIALIZATION RIGHTS OF AN INNOVATIVE THERMOSENSITIVE EMBOLIC AGENT FOR THE TREATMENT OF LIVER CANCER AND ACQUIRED 100% EQUITY OF A C
Capital/Financing Update
2021-05-26 English
VOLUNTARY ANNOUNCEMENT: THE GLOBAL INNOVATION PRODUCT OF THE GROUP STC3141 ENROLLED AND DOSED THE FIRST FOUR PATIENTS FOR THE PHASE IIa CLINICAL TRIAL FOR COVID-19 IN BELGIUM
Regulatory Filings
2021-05-24 English
VOLUNTARY ANNOUNCEMENT: SIR-SPHERES Y-90 RESIN MICROSPHERES DOSED THE FIRST HCC PATIENT OF THE U.S. CLINICAL TRIAL
Regulatory Filings
2021-05-09 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2021
Share Issue/Capital Change
2021-05-03 English
Proxy form for the annual general meeting to be held on 1 June 2021 or any adjournment thereof
AGM Information
2021-04-29 English
NOTICE OF ANNUAL GENERAL MEETING
AGM Information
2021-04-29 English
GENERAL MANDATE TO REPURCHASE SHARES AND ISSUE NEW SHARES&#x3b; RE-ELECTION OF RETIRING DIRECTORS AND APPOINTMENT OF DIRECTORS&#x3b; AND NOTICE OF ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement
2021-04-29 English
Annual Report 2020
Regulatory Filings
2021-04-29 English
VOLUNTARY ANNOUNCEMENT: THE GLOBAL INNOVATION PRODUCT OF THE GROUP STC3141 WAS APPROVED TO COMMENCE PHASE IIa CLINICAL RESEARCH IN RELATED TO COVID-19 IN BELGIUM
Regulatory Filings
2021-04-19 English
VOLUNTARY ANNOUNCEMENT: ONCOSEC RECEIVED THE CE MARK CERTIFICATION FROM EU FOR ITS GENE ELECTROTRANSFER DEVICE GENPULSE
Regulatory Filings
2021-04-19 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2021
Share Issue/Capital Change
2021-04-07 English
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2020
Annual Report
2021-03-17 English
VOLUNTARY ANNOUNCEMENT: SIR-SPHERES Y-90 RESIN MICROSPHERES OBTAINED RECOMMENDATION FROM NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)&#x3b; AND SIRTEX OBTAINED AN APPROVAL FROM FDA TO CON
Regulatory Filings
2021-03-08 English
DATE OF BOARD MEETING
Regulatory Filings
2021-03-05 English
VOLUNTARY ANNOUNCEMENT: FIRST PATIENT DOSED IN THE PHASE 1B CLINICAL TRIAL FOR SEPSIS OF THE GROUP FIRST-IN-CLASS DRUG STC3141
Regulatory Filings
2021-03-03 English
VOLUNTARY ANNOUNCEMENT: DRUG REGISTRATION CERTIFICATE FOR BIMATOPROST EYE DROPS WAS ISSUED
Regulatory Filings
2021-03-03 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 28 FEBRUARY 2021
Share Issue/Capital Change
2021-03-02 English
POSITIVE PROFIT ALERT
Regulatory Filings
2021-02-21 English
CONNECTED TRANSACTION: ACQUISITION OF THE REMAINING SHAREHOLDING INTEREST IN EAST OCEAN MEDICAL (HONG KONG) COMPANY LIMITED
Capital/Financing Update
2021-02-08 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 JANUARY 2021
Share Issue/Capital Change
2021-02-02 English
CHANGE IN BOARD LOT SIZE
Share Issue/Capital Change
2021-01-15 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2020
Share Issue/Capital Change
2021-01-04 English